Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
ASLAN Pharmaceuticals Logo
ASLAN Pharmaceuticals Growth Score
58
CB Rank
144212
Heat Score
38
ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies.
Founded
obfuscation
DelistedPost-IPO Equity Singapore, Central Region, Singapore11-50 aslanpharma.com
Biotechnology
Health Care
Medical
Oncology
Pharmaceutical
Overview

ASLAN Pharmaceuticals
Total Funding
obfuscation
Growth Score
58
Heat Score
38

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score58
-1 pts
in past quarter
Heat Score 38
0 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
See more interactive data and historical milestones on desktop for the best experience

About ASLAN Pharmaceuticals

CB Rank
144212
ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies.
Founded
obfuscation
DelistedPost-IPO Equity Singapore, Central Region, Singapore11-50 aslanpharma.com
Biotechnology
Health Care
Medical
Oncology
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name ASLAN Pharmaceuticals Pte Ltd
Operating Status Active
Stock Symbol  NASDAQ:ASLN
Company Type For Profit
Founders  Carl Firth
About the Company
ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in clinical-stage immunology and oncology-focused biopharmaceuticals.
Phone Number 65-6222-4235
Contact Email contact@aslanpharma.com
Predictions & Insights

Products & Services

Eblasakimab
A monoclonal antibody targeting the IL-13 receptor alpha 1 to block signaling pathways involved in allergic inflammatory diseases such as atopic dermatitis.
Farudodstat
An oral inhibitor of dihydroorotate dehydrogenase (DHODH) under development for treating alopecia areata by modulating immune response.

Research & Development

ASLAN Pharmaceuticals is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 10
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - ASLAN Pharmaceuticals Logo
Post-IPO Equity - ASLAN Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ASLAN Pharmaceuticals Logo
Post-IPO Equity - ASLAN Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ASLAN Pharmaceuticals Logo
Post-IPO Equity - ASLAN Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ASLAN Pharmaceuticals Logo
Post-IPO Equity - ASLAN Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ASLAN Pharmaceuticals Logo
Post-IPO Equity - ASLAN Pharmaceuticals
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 10
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - ASLAN Pharmaceuticals Logo
Post-IPO Equity - ASLAN Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ASLAN Pharmaceuticals Logo
Post-IPO Equity - ASLAN Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ASLAN Pharmaceuticals Logo
Post-IPO Equity - ASLAN Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ASLAN Pharmaceuticals Logo
Post-IPO Equity - ASLAN Pharmaceuticals
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ASLAN Pharmaceuticals Logo
Post-IPO Equity - ASLAN Pharmaceuticals
—
obfuscation
— Post-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 5 Contacts 12

Employee Profiles

News

News and Press

News•Sep 17, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Sep 17, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 25, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jun 25, 2025
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

69
32.69%
 in past month

Interest Signals

TopicSurge Score
TechRadar Logo
TechRadar
73

Actively Used Products

11ASLAN Pharmaceuticals uses 11 technology products and services including HTML5, F5 NGINX, and  Microsoft Outlook, according to G2 Stack.

Active Website Tech Count

21ASLAN Pharmaceuticals is actively using 21 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, SSL by Default, and  DNSSEC.

Total IP

38The intellectual property of ASLAN Pharmaceuticals includes 36 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, ASLAN Pharmaceuticals has registered 2 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is ASLAN Pharmaceuticals's headquarters? ASLAN Pharmaceuticals is located in Singapore, Central Region, Singapore.Who invested in ASLAN Pharmaceuticals? ASLAN Pharmaceuticals has 17 investors including K2 HealthVentures and  Armentum Partners.When was the last funding round for ASLAN Pharmaceuticals? ASLAN Pharmaceuticals closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are ASLAN Pharmaceuticals's competitors? Alternatives and possible competitors to ASLAN Pharmaceuticals may include Alumis, Septerna, and  Spyre Infostructure.How much funding has ASLAN Pharmaceuticals raised to date? ASLAN Pharmaceuticals has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5d46e5f 1)
|